Devices Oncology

 News Release - July 26, 2006

IntraOp Medical Receives Order for First Mobetron(R) in China

IntraOp Secures 19th Mobetron Order Worldwide

SUNNYVALE, Calif.--(HSMN NewsFeed)--July 26, 2006--IntraOp Medical Corporation (OTCBB: IOPM ) has received an order for its first Mobetron System in China. It will be the fourth Mobetron acquired by a hospital in Asia, and the 19th worldwide.

The Mobetron is an FDA-approved, easily transportable electron-beam instrument designed for intraoperative electron radiation therapy (IOERT), or the direct application of radiation to a tumor while a patient is undergoing cancer surgery. This first Chinese order will be installed at Beijing Tumor Hospital, China's premier cancer research and treatment center, often called the "National Cancer Institute of China," and a part of Beijing University Medical Center. In addition to treating patients, the hospital will use the Mobetron to train other Chinese practitioners in the use of IOERT and develop and expand the use of IOERT throughout China.

"Working with Beijing Tumor Hospital is a noteworthy opportunity for IntraOp Medical, the Mobetron and IOERT in general. Not only does this institution influence other cancer programs in China, it also has outstanding clinical research facilities," said Dr. Donald Goer, President and Chief Executive Officer of IntraOp. "We are expecting the Tumor Hospital to take an active role in coordinating IOERT studies throughout the Far East."

Dr. Peter Yu, IntraOp's Director of Far East Operations, said: "We have been working diligently to place a Mobetron at this prestigious center. Many other cancer hospitals in China will be watching to see how well the Mobetron integrates with Beijing Tumor Hospital's cancer program, and we expect other hospitals to follow its lead. From my discussions with the Tumor Hospital staff, I have learned that, in addition to the treatment of advanced and recurrent disease, which is typical of centers with IOERT capability, this hospital will use the Mobetron to treat lung cancer and early-stage breast cancer as well."

About Beijing Tumor Hospital

Beijing Tumor Hospital is the teaching, research and treatment hospital of the Beijing University Medical School, focusing on the prevention, treatment and rehabilitation of cancer patients. With 400 beds, the institution treats 6,000 patients per year. In addition to a modern radiotherapy department, the center boasts one of the most advanced tumor molecular biology laboratories in the world.

About IntraOp Medical Corporation

IntraOp Medical Corporation improves the quality of life for cancer patients through the development, manufacturing and sales of its proprietary Mobetron system. The Mobetron is a mobile electron-beam accelerator designed exclusively for intraoperative electron radiation therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery. The system makes IOERT widely available, cost effective, and simple to deliver because it is easily transportable between operating rooms and does not require a cost-prohibitive, radiation shielded surgical suite. The system is FDA-certified for sale in the United States and has received the equivalent foreign approvals: CE Mark in Europe, JIS in Japan and SDA in China. IntraOp Medical Corporation is based in Sunnyvale, California. For more information please visit www.intraopmedical.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Source: IntraOp Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.